Nonmalignant Hematologic Disorders

Review expert perspectives on key findings in nonmalignant hematologic disorders presented at the 2017 ASH annual meeting.

Share

Supporters

This activity is supported by independent educational grants from

Novartis Pharmaceuticals Corporation